Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Mindray's Quarter Won't Settle Diddly

Both bulls and bears can find information in Mindray's (NYSE:MR) second quarter report to uphold their preexisting biases about the stock. Convinced that that growth is slowing and the company is seeing less margin leverage? There are data to support that. Convinced that Mindray can continue to exploit a huge market for quality value-priced medical equipment while generating good free cash flow? We've got you covered there too.

At a minimum, I'd say Mindray is in that awkward phase where the company is alienating pure med-tech growth investors, but not yet attracting the margin/cash flow-driven value/GARP crowd. Although I think recent ventures into immunoassay and ultrasound could pay off down the road, I'm not as willing to...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details